Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy.

Abstract

In 5 patients with multiple system atrophy, administration of 15 mg/day of amezinium metilsulfate, an adrenergic agent, during 6 months for the treatment of postural hypotension exacerbated post-micturition residuals as compared to that before treatment (178 ml versus 113 ml for a change of 37 %, p < 0.05). Amezinium metilsulfate most probably stimulates both alpha1B-receptors in the vascular wall and alpha1A/D-receptors in the proximal urethra.

• Authors: Ryuji Sakakibara, Tomoyuki Uchiyama, Masato Asahina, Mitsuharu Yoshiyama, Tomonori Yamanishi, Takamichi Hattori
• Journal: Clinical autonomic research : official journal of the Clinical Autonomic Research Society (Clin Auton Res) Vol. 13 Issue 1 Pg. 51-3 (Feb 2003) ISSN: 0959-9851 [Print] Germany
• PMID: 12664248 (Publication Type: Journal Article)

Chemical References

• Pyridazines
• Sympathomimetics
• amezinium

Topics

• Aged
• Female
• Humans
• Male
• Middle Aged
• Multiple System Atrophy (complications)
• Pyridazines (adverse effects, therapeutic use)
• Retrospective Studies
• Sympathomimetics (adverse effects, therapeutic use)
• Urinary Retention (chemically induced)
• Urodynamics (drug effects, physiology)